Verapamil, a calcium channel blocker, can diminish the release of IL-1β and TNF-α into the vitreous fluid and decrease retinal ganglion cell loss in diabetic retinopathy via inhibiting NLRP3 inflammasome mediated by TLR4 (106). The gene discussed is NLRP3; the disease is diabetic retinopathy.